EcoR1 Capital, LLC bought $4.7M of Atara Biotherapeutics (ATRA)
Executed May 7, disclosed May 11, 4 days later.
Over the 21 trading sessions from the disclosed entry session (May 11), the stock returned +10.6% (delay-adjusted); from the execution session (May 7), +26.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
EcoR1 Capital, LLC (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Zymeworks Inc. (ZYME). Across 2 priced purchase filings, the average 21-session return was +2.8% from execution and -5.0% from disclosure (delay-adjusted; derived). The largest single filing was $40.0M of AKTS (2,222,222 sh across 2 lots, as filed), executed Jan 12.
Healthcare · Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the U…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→